Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Depomed Inc    DEPO

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Back to the USD 7 level

share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes
02/13/2013 | 03:19pm

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year. In addition the publication of the third quarter of 2012 showed an incredible growth of turnover by more than 100% at USD 33.3 million compared to the same period the previous year. The growing business should allow the security to continue its ascension.

Technically, the security is in an uptrend on all time scales. Prices are coming back to the USD 6.6 short term support, level corresponding to the 20-day moving average. This configuration should allow the stock to bounce towards the USD 7 long term resistance, which will be the first target price.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 7 resistance. A stop loss will be placed under the USD 6.6 short term support to avoid a downtrend.

© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 264 M
EBIT 2018 118 M
Net income 2018 -80,2 M
Debt 2018 624 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 3,97x
EV / Sales 2019 3,61x
Capitalization 424 M
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio -
Yield -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders
Duration : Period : Week
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders